eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
Study Findings Help Design Next-Generation Nanocarriers
Researchers believe that atomic-scale design of pharmaceuticals will be instrumental in producing more accurate and efficient drugs. Nanocarriers are engineered particles capable of holding tiny molecules inside their hollow interiors. Antibodies, which are bonded to the outer surface of these nanocarriers, function as markers to target specific cells or tissues or supply drugs to infected…
A bionic prosthetic eye that speaks the language of your brain
Sheila Nirenberg of Cornell University has been trying to work out how the retina in your eye communicates with your brain — and judging by a recent talk at TEDMED, it seems like she’s actually cracked it. Nirenberg produced mathematical equations that, with startling accuracy, encode images into neuron pulses that can be understood by an…
Groundbreaking Research Published in Collaboration with the National Eye Institute
We are thrilled to announce the publication of our latest research in eLife. This milestone represents an inspiring collaboration between EyeCRO and the esteemed laboratory of Dr. Anand Swaroop at the National Eye Institute. Our partnership exemplifies how teamwork and shared vision can advance the frontiers of science and medicine, particularly in the development of…
Calcium carbonate templates for drug delivery
The fast and targeted delivery of drugs to the focus of a disease could soon be made easier. Helmuth Möhwald and his colleagues from the Max Planck Institute of Colloids and Interfaces in Golm, Potsdam, have developed a simple technique for the production of drug containers which can be channelled to a selected target in…
Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?
“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN[1] and REACT[2] studies showed that treat-and-extend regimens for ranibizumab were efficacious for DME. Further support was provided by the TREX-DME study, the first prospective, randomized controlled…
Intraocular therapy prevents or reverses diabetic retinopathy in mice
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on…